Mild cognitive impairment: advantages of a comprehensive neuropsychological assessment

E I Drexler, B Voss, K Amunts

  • 1Department of Psychiatry, Psychotherapy and Psychosomatics, Medical School, RWTH Aachen University; Pauwelsstrasse 30, D-52074 Aachen, Germany. bivoss@ukaachen.de.

Insights

Mild cognitive impairment (MCI) is a heterogeneous condition. This study found a high prevalence of MCI using comprehensive testing, with memory impairment being predominant.

Area of Science:

  • Neuroscience
  • Gerontology
  • Psychology

Background:

  • Mild cognitive impairment (MCI) is a potential early dementia marker.
  • Current MCI diagnosis often uses limited tests and debates subjective complaints.
  • MCI heterogeneity necessitates comprehensive diagnostic approaches.

Purpose of the Study:

  • To investigate MCI characteristics using a broad test battery.
  • To assess MCI without requiring subjective cognitive complaints.
  • To determine MCI prevalence and cognitive domain involvement.

Main Methods:

  • 130 participants from the HelMA longitudinal study were assessed.
  • A comprehensive neuropsychological test battery was administered.
  • Participants were diagnosed as normally-aging controls or MCI.

Main Results:

  • MCI prevalence was 46.2%, higher than most estimates.
  • MCI patients showed deficits across all 29 tests.
  • Memory was the most frequently impaired domain; no purely non-amnestic cases were found.

Conclusions:

  • Comprehensive test batteries are crucial for accurate MCI assessment.
  • MCI diagnosis should consider multiple cognitive domains.
  • Findings challenge existing notions of MCI heterogeneity and prevalence.

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...